These findings provide new insight into the immunometabolic role of IRF5 and its potential broad clinical implications, including the importance of understanding sex-specific differences (e.g., for personalized medicine or risk stratification) and its potential as a sex-specific biomarker or therapeutic target in obesity-related metabolic disease, such as diabetes and tissue inflammation. This evidence concerns the gene IRF5 and Other metabolic disease.